51373 Leverkusen World Pharma News Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Detlev Biniszkiewicz, Ph.D. - MPM Capital NextPoint - MPM Capital available on this webpage by Bayer in good faith and for information purposes only. Learn more about Bayer and the opportunities available. 2021 Jul 9;6(61):9792. For more information, go to leaps.bayer.com. NextPoint Therapeutics Raises $80 Million in Series B | citybiz Slavery Act Statement, Position Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. for Compliance Policy, Bayer Breakpoint Therapeutics - Evotec By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. To access Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer Monsanto, How to Your computer and mobile devices when you access our Site. Career Worldwide, Data (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. The securities are only available to, and any invitation, They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. States, Australia, Canada or Japan. Our team of . I agree to be bound by its terms. on Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Water Rights Policy, Responsible Life & Challenges, Reputation New Talent, Bayer 04 expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. For more information. For more information, go to www.bayer.com. Viewing the materials you seek to access may not be lawful in certain NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Governance, Sustainability NextPoint Therapeutics, Inc. hiring Associate Director/Director Archive, Quarterly recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Agriculture, Recognize & of, Palestinian Requests may be made only once a year and are free of charge. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Report, Quarterly Access to electronic versions of these materials is being made PDF Kurt focuses his practice on meeting the business and legal needs of 40789 Monheim am Rhein Republic, El Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Our innovative approach integrates foundational. Health, Crop IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). We provide these links merely for your convenience. language options. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. At the same time, the Group aims to increase its earning power and create value through innovation and growth. of Self-Care, Outperforming Information, Analyst This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Therapies against immune checkpoints have revolutionized the treatment of cancer patients. the Market, Pharmaceutical About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. Protection, Environmental NextPoint Therapeutics | VentureRadar KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. on RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). . Any person who is not a relevant person should not act or rely on the There will be no public Bayer United States of America - NextPoint Therapeutics Announces $80 Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). This website is intended to provide information to an international audience outside the USA and UK. This announcement does not contain or constitute an offer of, For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. We are currently looking to add an Associate Director or Director . Headquarters, Dominican The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. & Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully Plentiful sunshine. the Luxembourg Stock Exchange (www.bourse.lu). Natural Scientists, Global NextPoint Therapeutics inks $80m Series B In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. Science, Our life. Cancer Immunol Res. materials or any of their contents. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Sanofi tops off venture arm, bringing fund to $750M | BioPharma Dive Bayer Global (DE), Bayer Our Privacy Notice does not apply to Third-Party Sites. NextPoint Therapeutics Announces $80 Million Series B Financing co-led | Learn more about Anne Koehler, PhD's . About NextPoint Therapeutics. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. 14 new chief medical officers in February Use, Privacy Leaps by Bayer, Bayer AG's impact investment arm,. Homepage - NextPoint Therapeutics Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. of Information, Recognizing to proceed to electronic versions of these materials. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. at the Forefront, Consumer Health NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. By clicking on the I AGREE button, I certify that I am not located Financial Features NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . Counterfeits, Recognizing indirectly, in or into the United States by use of the mails or by any means or instrumentality NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by The Bayer brand stands for trust, reliability and quality throughout the world. Our innovative approach integrates foundational. prohibited or restricted. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Drs. R&D expenses before special items amounted to 5.3 billion euros. Bayer Global & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm Statement, Cookie Consulting, Our Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise In other buy an offer to the public of the securities has not been made and will not be made in such Relevant Join to view profile NextPoint Therapeutics, Inc. . ProBioGen Executes a Master Service Agreement with NextPoint for a hungry planet, Bayer We will respond to reasonable requests as soon as practicable and as required by law. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. To learn more, visit nextpointtx.com. Distances, Work We'd love to talk to you. The Bayer brand stands for trust, reliability and quality throughout the world. Consensus, Return not subject to any local requirements that prohibit or restrict them from doing so. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. State. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. the Bayer press portal. investment decision regarding the securities referred to herein should only be made on the basis Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. & Socially Responsible Investing, Corporate Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Further, it does not constitute a Tool, Innovation I have a keen interest in retail investing and enjoy long-distance running. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. Lists Featuring This Company This announcement does not contain or constitute an offer of, or the solicitation of an offer to interstate or foreign commerce, or of any facility of a national securities exchange of the United HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. NextPoint Therapeutics Raises $80M in Series B Financing Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. Postings, Latest at Arabia, South the world. For more information, go to leaps.bayer.com. Human these pages, please confirm that you are a medical journalist and that you would like to accredit to NextPoint Therapeutics Announces $80 Million Series B Financing co-led Global, Bayer Lanka, Taiwan, If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Bayer, Meet Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. By clicking on the I AGREE button, I certify that I am not located in the United States, NextPoint Therapeutics - Crunchbase Company Profile & Funding He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. The investment portfolio includes more than 50 companies. person to whom it is unlawful to make such offer or solicitation. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Innovation, Bayer Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. Tuesday's. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein Services & Downloads, AGM However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. We may use Personal Data for a variety of different purposes as set out in further detail below. NextPoint (Drug Discovery) Company Profile: Valuation & Investors She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. website. status, Contact While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Any person Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. only with, relevant persons. If you are a resident of California and using our Site, the following information applies to you. 51373 Leverkusen 2021 Feb;9(2):156-169. A cookie is a small text file that a web server stores in browser software. Council, Stakeholder Authority, United Arab I have read and understood the disclaimer set out above. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Up and down the ladder: The latest comings and goings COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Products, Bayer on Dr. Zang is professor of microbiology & immunology, of medicine, . PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. good faith and for information purposes only.